<DOC>
	<DOCNO>NCT01342237</DOCNO>
	<brief_summary>The investigator plan improve event free survival rate reduce treatment related toxicity pediatric patient high risk/recurrent CNS tumor administrate tandem high dose chemotherapy autologous stem cell rescue .</brief_summary>
	<brief_title>Tandem High Dose Chemotherapy Autologous Stem Cell Rescue High Risk Pediatric Brain Tumors</brief_title>
	<detailed_description>High risk/recurrent central nervous system ( CNS ) tumor poor prognosis tandem high dose chemotherapy ( HDCT ) hematopoietic progenitor stem cell rescue choose potentially curative therapy . Many institution use carboplatin , thiotepa , etoposide ( CTE ) condition regimen 1st HDCT cyclophosphamide , melphalan ( CM ) condition regimen 2nd HDCT . Our institution apply regimen 38 pediatric patient high risk brain tumor since 1996 . Although 3 year overall survival rate event free survival rate improve 69 % 47.9 % , respectively , result show relatively high treatment relate mortality ( TRM ) rate 21 % . Toxicity tandem regimen also report high 32 % research well regimen consider feasible due toxicity . In study , investigator plan improve event free survival rate reduce treatment related toxicity pediatric patient high risk/recurrent CNS tumor administrate tandem high dose chemotherapy autologous stem cell rescue topotecan , thiotepa , carboplatin ( TTC ) 1st HDCT melphalan , etoposide , carboplatin ( MEC ) 2nd HDCT .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>1 . High risk pediatric brain tumor Newly diagnose medulloblastoma , CNS PNET , ATRT , Choroid plexus carcinoma , pineoblastoma residual tumor 1.5cm2 operation leptomeningeal seed diagnosis 2 . All high grade malignant brain tumor , age &lt; 3 year 3 . Recurrent embryonal brain tumor , recurrent CNS germ cell tumor 4 . Age : limitation 5 . Performance status : ECOG 02 . 6 . Patients must free significant functional deficit major organ , follow eligibility criterion may modify individual case . Heart : shortening fraction ≥ 28 % . Liver : total bilirubin &lt; 2 ⅹ upper limit normal ; ALT &lt; 3 ⅹ upper limit normal . Kidney : creatinine &lt; 2 ⅹ normal creatinine clearance ( GFR ) &gt; 60 ml/min/1.73m2 . 7 . Patients must lack active viral infection active fungal infection . 8 . Patients ( one parent patient age &lt; 20 ) sign inform . 1 . Patients reach partial response prior high dose chemotherapy . 2 . Pregnant nursing woman . 3 . Malignant ( except brain tumor ) nonmalignant illness uncontrolled whose control may jeopardize complication study therapy . 4 . Psychiatric disorder would preclude compliance . 5 . Patients , opinion investigator , may able comply safety monitoring requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Brain tumor</keyword>
	<keyword>Stem cell transplantation</keyword>
	<keyword>topotecan</keyword>
	<keyword>thiotepa</keyword>
	<keyword>carboplatin</keyword>
	<keyword>melphalan</keyword>
	<keyword>etoposide</keyword>
</DOC>